Biomarin Pharmaceutical Stock Buy Hold or Sell Recommendation
| BMRN Stock | USD 63.88 0.42 0.66% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Biomarin Pharmaceutical is 'Strong Hold'. The recommendation algorithm takes into account all of Biomarin Pharmaceutical's available fundamental, technical, and predictive indicators you will find on this site.
Check out Biomarin Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide. In addition, we conduct extensive research on individual companies such as Biomarin and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Biomarin |
Execute Biomarin Pharmaceutical Buy or Sell Advice
The Biomarin recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biomarin Pharmaceutical. Macroaxis does not own or have any residual interests in Biomarin Pharmaceutical or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biomarin Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Biomarin Pharmaceutical Trading Alerts and Improvement Suggestions
| Biomarin Pharmaceutical generated a negative expected return over the last 90 days | |
| Biomarin Pharmaceutical is unlikely to experience financial distress in the next 2 years | |
| Biomarin Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 85209 shares by Bienaime Jean Jacques of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3 |
Biomarin Pharmaceutical Returns Distribution Density
The distribution of Biomarin Pharmaceutical's historical returns is an attempt to chart the uncertainty of Biomarin Pharmaceutical's future price movements. The chart of the probability distribution of Biomarin Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Biomarin Pharmaceutical price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biomarin Pharmaceutical returns is essential to provide solid investment advice for Biomarin Pharmaceutical.
| Mean Return | -0.13 | Value At Risk | -3.49 | Potential Upside | 1.63 | Standard Deviation | 1.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biomarin Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biomarin Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Biomarin Pharmaceutical, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Biomarin Pharmaceutical back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-09-30 | 2.8 M | Bank Of New York Mellon Corp | 2024-09-30 | 2.3 M | Venbio Select Advisor Llc | 2024-09-30 | 2 M | Deutsche Bank Ag | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Legal & General Group Plc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.3 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.2 M | Blackrock Inc | 2024-09-30 | 22.6 M | Vanguard Group Inc | 2024-09-30 | 19.3 M |
Biomarin Pharmaceutical Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (61.2M) | (35.1M) | (68.3M) | (157.1M) | (141.4M) | (134.3M) | |
| Change In Cash | 211.7M | (61.9M) | 137.3M | 30.6M | 35.2M | 31.7M | |
| Free Cash Flow | (52.2M) | 185.3M | 44.4M | 51.6M | 46.5M | 48.8M | |
| Depreciation | 105.2M | 108.0M | 102.0M | 104.4M | 120.0M | 126.0M | |
| Other Non Cash Items | 44.7M | 12.9M | (115.5M) | 61.6M | 70.9M | 74.4M | |
| Capital Expenditures | 137.5M | 119.2M | 131.5M | 107.6M | 123.8M | 88.6M | |
| Net Income | 859.1M | (64.1M) | 141.6M | 167.6M | 192.8M | 202.4M | |
| End Period Cash Flow | 649.2M | 587.3M | 724.5M | 755.1M | 868.4M | 911.8M | |
| Investments | 26.2M | (366.3M) | (20.0M) | (101.0M) | (90.9M) | (95.4M) | |
| Change Receivables | (54.3M) | (37.9M) | (59.0M) | 65.6M | 75.4M | 79.2M | |
| Net Borrowings | (5.1M) | 210.8M | (3.0M) | (2.6M) | (2.3M) | (2.2M) | |
| Change To Netincome | 56.7M | (671.6M) | 185.2M | 28.8M | 25.9M | 27.2M |
Biomarin Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biomarin Pharmaceutical or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biomarin Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biomarin stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.14 | |
β | Beta against Dow Jones | -0.0034 | |
σ | Overall volatility | 1.61 | |
Ir | Information ratio | -0.14 |
Biomarin Pharmaceutical Volatility Alert
Biomarin Pharmaceutical exhibits very low volatility with skewness of -0.47 and kurtosis of 2.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biomarin Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biomarin Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biomarin Pharmaceutical Fundamentals Vs Peers
Comparing Biomarin Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biomarin Pharmaceutical's direct or indirect competition across all of the common fundamentals between Biomarin Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biomarin Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biomarin Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biomarin Pharmaceutical to competition |
| Fundamentals | Biomarin Pharmaceutical | Peer Average |
| Return On Equity | 0.0625 | -0.31 |
| Return On Asset | 0.03 | -0.14 |
| Profit Margin | 0.12 % | (1.27) % |
| Operating Margin | 0.15 % | (5.51) % |
| Current Valuation | 11.77 B | 16.62 B |
| Shares Outstanding | 190.58 M | 571.82 M |
| Shares Owned By Insiders | 0.87 % | 10.09 % |
| Shares Owned By Institutions | 97.73 % | 39.21 % |
| Number Of Shares Shorted | 4.38 M | 4.71 M |
| Price To Earning | 220.73 X | 28.72 X |
| Price To Book | 2.23 X | 9.51 X |
| Price To Sales | 4.42 X | 11.42 X |
| Revenue | 2.42 B | 9.43 B |
| Gross Profit | 1.44 B | 27.38 B |
| EBITDA | 310.28 M | 3.9 B |
| Net Income | 167.65 M | 570.98 M |
| Cash And Equivalents | 1.27 B | 2.7 B |
| Cash Per Share | 6.85 X | 5.01 X |
| Total Debt | 1.1 B | 5.32 B |
| Debt To Equity | 0.24 % | 48.70 % |
| Current Ratio | 5.15 X | 2.16 X |
| Book Value Per Share | 28.41 X | 1.93 K |
| Cash Flow From Operations | 159.26 M | 971.22 M |
| Short Ratio | 3.14 X | 4.00 X |
| Earnings Per Share | 1.66 X | 3.12 X |
| Price To Earnings To Growth | 0.40 X | 4.89 X |
| Target Price | 97.16 | |
| Number Of Employees | 3.4 K | 18.84 K |
| Beta | 0.31 | -0.15 |
| Market Capitalization | 12.17 B | 19.03 B |
| Total Asset | 6.84 B | 29.47 B |
| Retained Earnings | (621.55 M) | 9.33 B |
| Working Capital | 1.78 B | 1.48 B |
Note: Disposition of 85209 shares by Bienaime Jean Jacques of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3 [view details]
Biomarin Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biomarin . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 13655.43 | |||
| Daily Balance Of Power | 0.525 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 63.83 | |||
| Day Typical Price | 63.85 | |||
| Price Action Indicator | 0.26 | |||
| Period Momentum Indicator | 0.42 |
About Biomarin Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Biomarin Pharmaceutical? Buying financial instruments such as Biomarin Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biomarin Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Services Thematic Idea Now
Business Services
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Services theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biomarin Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share | Quarterly Revenue Growth 0.283 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.